Aurobindo Pharma Limited has announced the launch of Cinacalcet Hydrochloride Tablets (30mg, 60mg and 90mg) at risk in the US market in accordance with the terms of settlement agreement with Amgen Inc. Aurobindo's Cinacalcet Hydrochloride tablets 30mg, 60mg and 90mg is a generic version of Amgen Inc's Sensipar® tablets, Cinacalcet Hydrochloride tablets had an annual sale of approximately US$ 1,449 million for the twelve months ending May 2019 as per IQVIA.
Cinacalcet Hydrochloride tablets are indicated for the treatment of:
- Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKO) on dialysis
- Hypercalcemia in adult patients with parathyroid carcinoma
- Severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy
Shares of AUROBINDO PHARMA LTD. was last trading in BSE at Rs.597.4 as compared to the previous close of Rs. 604.1. The total number of shares traded during the day was 89737 in over 3007 trades.
The stock hit an intraday high of Rs. 606 and intraday low of 589.25. The net turnover during the day was Rs. 53672087.